Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Mar 15, 2024 (filed on Mar 19, 2024)Insider Name:Winningham Rick EOwnership Type:Indirect OwnershipSecurities:Ordinary SharesNature of Transaction:G - Gift# or value acquired/disposed of:3,900Price:--
-
Mar 15, 2024 (filed on Mar 19, 2024)Insider Name:Winningham Rick EOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:G - Gift# or value acquired/disposed of:-3,900Price:--
-
Mar 15, 2024 (filed on Mar 19, 2024)Insider Name:Winningham Rick EOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:G - Gift# or value acquired/disposed of:-7,000Price:--
-
Mar 15, 2024 (filed on Mar 19, 2024)Insider Name:Winningham Rick EOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:2,704Price:$8.64
-
Feb 22, 2024 (filed on Feb 22, 2024)Insider Name:Farnum RhondaOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-1,254Price:$8.71
-
Feb 20, 2024 (filed on Feb 22, 2024)Insider Name:Winningham Rick EOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-37,196Price:$8.92
-
Feb 20, 2024 (filed on Feb 22, 2024)Insider Name:Sawaf AzizOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-17,036Price:$8.92
-
Feb 20, 2024 (filed on Feb 22, 2024)Insider Name:Miller AineOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-11,782Price:$8.92
-
Feb 20, 2024 (filed on Feb 22, 2024)Insider Name:Grimaud Brett A.Ownership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-17,595Price:$8.92
-
Feb 20, 2024 (filed on Feb 22, 2024)Insider Name:Graham Richard AOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-19,294Price:$8.92
Filings by filing date
-
Mar 15, 2024 (filed on Mar 19, 2024)Insider Name:Winningham Rick EOwnership Type:Indirect OwnershipSecurities:Ordinary SharesNature of Transaction:G - Gift# or value acquired/disposed of:3,900Price:--
-
Mar 15, 2024 (filed on Mar 19, 2024)Insider Name:Winningham Rick EOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:G - Gift# or value acquired/disposed of:-3,900Price:--
-
Mar 15, 2024 (filed on Mar 19, 2024)Insider Name:Winningham Rick EOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:G - Gift# or value acquired/disposed of:-7,000Price:--
-
Mar 15, 2024 (filed on Mar 19, 2024)Insider Name:Winningham Rick EOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:2,704Price:$8.64
-
Feb 20, 2024 (filed on Feb 22, 2024)Insider Name:Winningham Rick EOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-37,196Price:$8.92
-
Feb 20, 2024 (filed on Feb 22, 2024)Insider Name:Sawaf AzizOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-17,036Price:$8.92
-
Feb 20, 2024 (filed on Feb 22, 2024)Insider Name:Miller AineOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-11,782Price:$8.92
-
Feb 20, 2024 (filed on Feb 22, 2024)Insider Name:Grimaud Brett A.Ownership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-17,595Price:$8.92
-
Feb 20, 2024 (filed on Feb 22, 2024)Insider Name:Graham Richard AOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-19,294Price:$8.92
-
Feb 22, 2024 (filed on Feb 22, 2024)Insider Name:Farnum RhondaOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-1,254Price:$8.71
News
Biz Brief
Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN KY1-1104 |
Tel: | N/A |
Website: | https://www.theravance.com |
IR: | See website |
Key People | ||
Rick E. Winningham Chairman of the Board, Chief Executive Officer | Aziz Sawaf Chief Financial Officer, Senior Vice President | Brett A. Grimaud Senior Vice President, General Counsel, Secretary | Rhonda F. Farnum Senior Vice President - Commercial and Medical Affairs, Chief Business Officer |
Business Overview |
Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the development, and commercialization of medicines. Its product, YUPELRI (revefenacin) inhalation solution is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). YUPELRI is a prescription medicine used to treat COPD, a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath and others. Its pipeline of internally discovered programs is targeted to address unmet patient needs. Ampreloxetine, its late-stage investigational norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension. Its Selective 5-HT4 Agonist (TD-8954) is a selective 5-HT4 receptor agonist, which is developed for the treatment of gastrointestinal motility disorders. |
Financial Overview |
For the fiscal year ended 31 December 2023, Theravance Biopharma Inc revenues increased 12% to $57.4M. Net loss before extraordinary items decreased 41% to $55.2M. Revenues reflect Europe segment increase of less than 1% to $223K. Lower net loss reflects Research and development - bal decrease of 36% to $32.6M (expense), Restructuring and related expenses decrease of 79% to $2.7M (expense). |
Employees: | 99 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $331.54M as of Dec 31, 2023 |
Annual revenue (TTM): | $57.42M as of Dec 31, 2023 |
EBITDA (TTM): | -$51.29M as of Dec 31, 2023 |
Net annual income (TTM): | -$55.19M as of Dec 31, 2023 |
Free cash flow (TTM): | -$29.49M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 48,164,708 as of Feb 23, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |